ArticlePloS one2018
Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease between 2009 and 2021 in England: a series of cross-sectional and cohort studies.BMJ public health · 2026Article
- Association of Coenzyme Q10 Supplementation With Statin-Associated Muscle Symptoms in Long-Term Statin Users.Cureus · 2025Article
- Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data.Medicina (Kaunas, Lithuania) · 2025Article
- Under-Prescription of Drugs in the Elderly Population of Western Romania: An Analysis Based on STOPP/START Version 2 Criteria.Journal of clinical medicine · 2024Article
- The Causal-Benefit Model to Prevent Cardiovascular Events.JACC. Advances · 2024Review
- ASPC president's page: Getting back to basics one patient at a time.American journal of preventive cardiology · 2022Article
- Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.The Lancet. Global health · 2022Article
- Investigation of the Effect of Atorvastatin on Skeletal Muscles in Male Rats and the Involved Mechanisms.Archives of Razi Institute · 2022Article
- Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?Breathe (Sheffield, England) · 2020Article
- Primary Prevention of Cardiovascular Risk in Lithuania-Results from EUROASPIRE V Survey.Medicina (Kaunas, Lithuania) · 2020Observational
- Evaluation of cardiovascular risk in a lung cancer screening cohort.Thorax · 2019 · on this mapObservational
- Statin-Associated Muscle Disease: Advances in Diagnosis and Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Can we achieve ESC 2019 guidelines LDL-cholesterol target in Tunisia?La Tunisie medicaleArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundThe updated national guidelines for cardiovascular risk assessment and lipid modification in the UK and US expand the indications for statin therapy in primary prevention to adults with moderate risk of cardiovascular disease (CVD) but many adults at high CVD risk remain untreated in both countries. We set out to identify treatment gaps in English and American adults at moderate and high risk of cardiovascular disease (CVD), and to estimate the number of CVD events that would be prevented from expanding statin therapy to those who are currently untreated.
methodsWe used nationally representative samples of 10,375 English adults and 7,687 US adults aged 40-75 years and free of existing CVD from the Health Survey for England 2009-2013, and the National Health and Nutrition Examination Survey 2007-2012 in the US. We used the risk algorithms and the risk thresholds for statin therapy recommended by each country's national guideline to categorize the survey participants into moderate-risk (≥10% to <20% 10-year risk of CVD in England and ≥7.5% to <20% risk in the US) or high-risk (≥20%risk) and simulated the number of events that would be prevented from expansion of statin therapy to those currently untreated.
resultsClose to half of adults at high CVD risk in England (46.0%) and the US (49.7%) were not receiving statins. Expanding statin use to 1.45 million high-risk adults in England would save 101,000 (95% CI = 81,000-120,000) CVD events in the next 10 years compared with 128,000 (103,000-154,000) CVD events that would be prevented from expanding treatment to 3.64 million untreated moderate-risk adults. In the US, expanding statin use to 5.27 million untreated high-risk adults would save 384,000 (305,000-461,000) CVD events over 10 years compared with 616,000 (493,000-738,000) CVD events that would be prevented from treating 20.29 million untreated moderate-risk adults.
conclusionsIn both England and the US, expanding statin therapy to untreated moderate-risk adults would prevent a comparable number of events as expanding statin use to a much smaller number of currently untreated high-risk adults. A large potential for CVD prevention remains from improving coverage of statin therapy among high-risk adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.